港股收評:恆指國指均跌0.9% 生物醫藥類股午後大跌 電力板塊逆勢走強
格隆匯12月15日丨港股主要指數午後跌幅擴大,恆生科技指數指數一度跌超2%,收跌1.52%,恆指跌0.91%,國指跌0.9%。盤面上,生物醫藥類股午後大跌,藥明生物放量重挫超19%,康龍化成、信達生物等多隻個股跌幅超10%以上;半導體股、體育用品股、教育股、恆大概念股、家電股、汽車等板塊普跌,中芯國際跌超6%,比亞迪股份、小鵬汽車跌超2%。另一方面,電力股全天維持強勢行情,華潤電力盤中再創新高,煤炭股、光伏股、港口航運股小幅走強。大型科技股偏普跌,百度跌近3%,小米跌超2%,騰訊等多數下跌,惟阿裏巴巴漲近2%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.